Insulin therapy of type II diabetes;Die Insulintherapie des Typ-II-Diabetes

Wiener Medizinische Wochenschrift

Volumn 147, Issue 9, 1997, Pages 211-216

  Beyer, J ^a   Kustner E ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

comparison of therapy; diabetes education; insulin therapy, conventional intensified; insulin therapy, functional intensified; type II diabetes

Indexed keywords

INSULIN; SULFONYLUREA DERIVATIVE;

DIET; HUMAN; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; SHORT SURVEY;

AGED; BLOOD GLUCOSE; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DIABETIC DIET; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; PATIENT EDUCATION; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0030997312     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (25)

1. Abraira C, Emanuele N, Colwell J, Henderson W, Comstock J, Levin S, Nuttall F, Sawin C (VA CS Group): Glycemie control and complications in typ II diabetics: Design of a feasibility trial. Diabetes Care 1992;15:1560-1571.
2. Alberti K-GMM, Gries FA: Management of non-insulin-dependent diabetes mellitus in Europe: a consensus view. Diab Med 1988;5:275-281.
3. American Diabetes Association: Implications of the Diabetes Control and Complication Trial. Position statement. Clin Diab 1993; 12:91-96.
4. American Diabetes Association: Consensus Statement: The pharmacological treatment of hyperglycemia in NIDDM. Diab Care 1995; 18:1510-1518.
5. Anderson DKG, Swardsudd K: Long-term glycemic control relates to mortality in Typ II diabetics. Diab Care 1995;18:1538-1543.
6. Bohannon NJV: Diabetes in the elderly: a unique set of management challenges. Postgrad Med 1988;84:283-295.
7. Genuth S: Insulin use in NIDMM. Diab Care 1990;13:1240-1264.
8. Hamelbeck H, Klein W, Zoltobrocki M, Schöffling K: Glibenclamid insulin combination in the management of the secondary failure of sulfonyl ura medication. Dtsch Med Wschr 1982;107:2581-1583.
9. Hauner H, Ferber Lv, Köster J: Schätzung der Diabeteshäuligkeit in der Bundesrepublik Deutschland anhand von Krankenkassendaten: Sekundärdatenanalyse einer repräsentativen Stichprobe AOK-Versicherter in der Stadt Dortmund. Dtsch Med Wschr 1992; 117: 645-650.
10. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS: Intensive Conventional Insulin Therapy for Type II Diabetes. Diab Care 1993;16:21-31.
11. Ho PJ, Turtle JR: Establishing the diagnosis. In Finucane P, Sinclair AJ (eds): Diabetes in old age. London, Wiley & Sons, 1995, pp 51-91.
12. Laube H, Heller M, Liersch J, Mäser E, Linn T: Erfahrungen mit Lispro-Insulin bei intensivierter Behandlung von Typ I- und Typ II-Diabetikern. Diab Stoffw 1996;5:273-276.
13. Lazarus SS, Volk BB: Physiological basis of the effectiveness of combined insulin-tolbutamide therapy in stabile diabetes. Ann N Y Acad Sci 1959;82:590-602.
14. Lindström TH, Arnquist HJ, Schenk HHv: Effect of Conventional and Intensified Insulin Therapy on Free-Insulin Profiles and Glycemic Control in NIDDM. Diab Care 1992;15:27-34.
15. Okkubo Y, Kishikawa H, Araki E, Miyate T, Isami S, Motoyoshi S, Kojima Y, Furuyoski N, Shiehiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diab Res Clin Pract 1995;28: 103-117.
16. Renner R, Liebl A, Jagusch W, Hepp K-D: Typ II-Diabetes mellitus: Insulinbehandlung älterer Patienten. Extr Geriatrica 1994; 3:12-17.
17. Riddle MC, Hart JS, Bouma DJ, Phillipson BE, Yonker G: Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type II diabetic subjects. Diabetes Care 1989;12:623-629.
18. Stenman S, Groop PH, Saloranta C, Tottermann KJ, Fyhrqvist F, Groop L: Effects of combination of insulin and glibenclamide in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral hypoglycaemic agents. Diabetologia 1988;31:206-213.
19. Taskinen MR, Same T, Helve E, Karonen SL, Nikkila EA, Yki-Jarvinen H: Bedtime insulin for suppression of over-night free fatty acid, blood glucose, and glucose production on NIDDM. Diabetes 1989; 38:580-588.
20. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
21. U. K. Prospective Study-Group: U. K. Prospective Diabetes Study (UKPDS): VIII Study design, progress and performance. Diabetologia 1991;34:877-890.
22. UKPDS Study-Group: Relative efficacy of randomly allocated diet, sulfonylurea, insulin or metformin in patients with newly diagnosed type 2 diabetes followed for three years. Br Med J 1995;310:83-88.
23. Van der Does FEE, Grotzenhuis PA, De Neeling JN, Bouter LM, Snoek FJ, Heine RJ, Kostense PJ: Symptoms and Well-Being in Relation to Glycemic Control in Type II Diabetes. Diab Care 1996; 19:204-210.
24. Wolfenbuttel BHR, Sels J-B, Rondas-Colbers JE, Gabrielle JWM, Menheerz PCA, Nieuwenhuijzeu-Kruseman Arie C: Comparison of Different Insulin Regimens in Elderly Patients with NIDDM. Diab Care 1996;19:1326-1332.
25. Yki-Jarvinen H, Kampila M, Kujanssure E, Lathi J, Marjanen T, Niskanen L, Rajala S, Ryysy L, Salo S, Seppala P: Comparison of insulin regimes in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992;327:1426-1433.